Abstracts tagged "Lupus"

Abstract Number: 1082 • 2018 ACR/ARHP Annual Meeting
Peripheral Blood CD11c+ CD21- Age-Associated B Cells (ABCs) in Human Systemic Lupus Erythematosus Are Associated with Innate Type III Interferon and Disease Activity
Jennifer L. Barnas, Lin Gao, Mary O'Connell, Jennifer Albrecht, Nida Meednu, R. John Looney and Jennifer Anolik, Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by an interferon-stimulated gene (ISG) signature typically attributed to interferon (IFN)-α. However, ISGs can be induced by other…
Abstract Number: 1898 • 2018 ACR/ARHP Annual Meeting
Type I Interferon-Induced Proteins May Facilitate the Occurrence of Long QT Syndrome (LQTS) in Parallel with Anti-Ro/SSA and Anti-Ro52/TRIM21 Antibody Levels in Patients with Systemic Lupus Erythematous (SLE): A Bench to Bedside Approach
Luis F. Perez-Garcia^1,2, Irving O. Estevez-Garcia³, Ricardo Marquez-Velasco³, Pedro Iturralde⁴, Luis H. Silveira⁵ and Luis M. Amezcua-Guerra^2,6,7, ¹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ²Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ³Immunology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ⁴Cardiology - Electrophysiology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ⁵Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City DF, Mexico, ⁶Cardiovascular Research Laboratory, Unidad de Investigacion Traslacional, Universidad Nacional Autonoma de Mexico/Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ⁷Department of Health Care, Universidad Autonoma Metropolitana, Xochimilco, Mexico City, Mexico
Background/Purpose: Long QT syndrome (LQTS) is an abnormal QT corrected (QTc) interval prolongation, strongly associated with increased risk of sudden death. Studies have associated LQTS…
Abstract Number: 2645 • 2018 ACR/ARHP Annual Meeting
The Impact of Metformin on Disease Activity in Systemic Lupus Erythematosus
Cara McLeod¹, Gbemisola Olayemi¹, Nitasha Bhatia², Frank Migliore³ and Robert Quinet¹, ¹Rheumatology, Ochsner Medical Center, New Orleans, LA, ²Ochsner Medical Center, New Orleans, LA, ³Rheumatology, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Metformin is a mainstay of therapy for type 2 diabetes mellitus. Newer evidence suggests that metformin may reduce lupus flares. An entity called neutrophil…
Abstract Number: 296 • 2017 ACR/ARHP Annual Meeting
A Module of Genes Describing Low Density Granulocytes Can be Identified and Followed in the Periphery of Lupus Patients
Brian Keggereis¹, Michelle Catalina², Nick Geraci¹, Sarah Heuer², Prathyusha Bachali², Sushma Madamanchi², Peter E. Lipsky² and Amrie Grammer², ¹AMPELBioSolutions and RILITE Research Institute, Charlottesville, VA, ²AMPEL BioSolutions and RILITE Research Institute, Charlottesville, VA
Background/Purpose: Lupus is an autoimmune disease characterized by a type I interferon signature thought to be initiated by granulocyte NETosis. The granulocyte population in the…
Abstract Number: 1003 • 2017 ACR/ARHP Annual Meeting
Hair Treatments and the Risk of Systemic Lupus Erythematosus: the Michigan Lupus Epidemiology & Surveillance (MILES) Program
Emily C. Somers¹, Christina Mrukowicz², Wendy Marder¹, W. Joseph McCune³, Afton L. Hassett⁴, Suzanna Zick⁵, Siobán Harlow⁶ and Caroline Gordon⁷, ¹Internal Medicine-Rheumatology, University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Int Med/ Rheum, University of Michigan, Ann Arbor, MI, ⁴Rheumatology, Emory University, Atlanta, GA, ⁵Department of Family Medicine, University of Michigan, Ann Arbor, MI, ⁶Epidemiology Department- School of Public Health, Obstetrics and Gynecology- Medical School, University of Michigan, Ann Arbor, MI, ⁷School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Hair dye exposure has been reported as a risk factor for systemic lupus erythematosus (SLE) and connective tissue diseases, though conflicting results exist. We…
Abstract Number: 1667 • 2017 ACR/ARHP Annual Meeting
Increased Levels of BAFF in SLE Patients Correlates with Neutrophil Activation and Autoantibody Production
Andrew Vasconcellos¹, John Marken¹, Ting Wang^1,2, Christian Lood³ and Natalia V. Giltiay¹, ¹Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, ²Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China, ³Division of Rheumatology, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA
Background/Purpose: Neutrophil (PMN) activation and neutrophil extracellular trap (NET) formation are implicated in the pathogenesis of Systemic Lupus Erythematosus (SLE), particularly in the acceleration of…
Abstract Number: 2590 • 2017 ACR/ARHP Annual Meeting
Subcutaneous Belimumab Plus Standard of Care Demonstrated Improvement in Multiple Organ Domains Versus Placebo Plus Standard of Care in Patients with Active Systemic Lupus Erythematosus (SLE)
Andrea Doria¹, Bonnie Pobiner², William Eastman³, Milena Kurtinecz⁴, Anne Hammer², James Groark⁵ and Damon Bass⁵, ¹Division of Rheumatology, University of Padova, Padova, Italy, ²GSK Research Triangle Park, Research Triangle Park, NC, ³GSK, Research Triangle Park, NC, ⁴GSK, Philadelphia, PA, ⁵GSK Collegeville, Collegeville, PA
Background/Purpose : Organ manifestation domain score improvement was assessed with subcutaneous (SC) belimumab (BEL) plus standard SLE care (SoC) in active, autoantibody-positive SLE. Methods: BLISS-SC…
Abstract Number: 300 • 2017 ACR/ARHP Annual Meeting
The DNA-Binding Protein ARID3a Is Associated with Interferon Alpha Production in Lupus Patient Plasmacytoid Dendritic Cells and Neutrophils
Michelle Ratliff¹, Joshua Garton^1,2, Indra Adrianto³, Ambra Pastori⁴, Courtney Montgomery⁵, Patrick Gaffney⁴, Judith A. James^3,6 and Carol Webb^1,7,8, ¹Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Chemistry, University of Oklahoma, Oklahoma City, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁷Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: We previously demonstrated over-expression of the DNA-binding protein ARID3a in peripheral blood B lymphocytes from patients with systemic lupus erythematosus (SLE) compared to healthy…
Abstract Number: 1026 • 2017 ACR/ARHP Annual Meeting
Gene Expression Analysis Reveals Common Pathways of Tissue Pathogenesis in Lupus Organ Involvement
Amrie Grammer¹, Sarah Heuer¹, Robert Robl¹, Adam Labonte¹, Prathyusha Bachali¹, Sushma Madamanchi¹ and Peter E. Lipsky², ¹AMPEL BioSolutions and RILITE Research Institute, Charlottesville, VA, ²AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Lupus is a prototypic autoimmune disease characterized by B cell hyperactivity, autoantibody formation and resultant tissue damage. The mechanisms underlying tissue pathology in lupus…
Abstract Number: 1669 • 2017 ACR/ARHP Annual Meeting
Anti-Mitochondria DNA Antibody As an Improved Biomarker for Systemic Lupus Erythematosus
Yangsheng Yu¹, Kalika Mahato¹, Suyang Xu¹, Jenna Mu¹, Amanda Zhang¹, James R. O'Dell², Lynell W. Klassen², Michelene Hearth-Holmes³ and Kaihong Su¹, ¹Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, ²Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine/Rheumatology Division, Univ. of Nebraska Medical Center, Omaha, NE
Background/Purpose: Anti-dsDNA antibodies are highly specific for systemic lupus erythematosus (SLE) and often associate with lupus nephritis. Extracellular nucleosome DNA released from apoptotic or necrotic…
Abstract Number: 2595 • 2017 ACR/ARHP Annual Meeting
The Role of Hydroxychloroquine in the Treatment of Undifferentiated Connective Tissue Disease
Hayley Epstein¹, Diana P. Pena², Bianca Di Cocco¹, Teja Kapoor³ and Anca Askanase⁴, ¹Rheumatology, CUMC, New York, NY, ²Rheumatology, Universidad Militar Nueva Granada, Bogotá, Colombia, ³Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁴Rheumatology, Columbia University Medical Center, New York, NY
Background/Purpose: To evaluate the change in ANA titers as a proxy for progression in patients with undifferentiated connective tissue disease (UCTD) treated with hydroxychloroquine (HCQ)…
Abstract Number: 354 • 2017 ACR/ARHP Annual Meeting
Multidomain Functional Assessment in a Cohort of Patients with Systemic Lupus Erythematosus: A Pilot Study
Laura Plantinga¹, Benjamin Tift², C. Barrett Bowling³, Charmayne M. Dunlop-Thomas⁴, S. Sam Lim⁵ and Cristina Drenkard⁵, ¹Department of Medicine, Emory University School of Medicine, Atlanta, GA, ²Edward Via College of Osteopathic Medicine, Spartanburg, SC, ³Durham Veterans Affairs Medical Center, Durham, NC, ⁴Emory University School of Medicine, Atlanta, GA, ⁵Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, complex disease with multiple comorbid conditions and non-disease-specific manifestations. Consequently, the impact of SLE on both physical…
Abstract Number: 1238 • 2017 ACR/ARHP Annual Meeting
The Development of the Lupus Foundation of America—Rapid Evaluation of Activity in Lupus (LFA-REAL™) Patient-Reported Outcome (PRO) to Evaluate Lupus Disease Activity
Anca Askanase¹, Samantha Nguyen², Miya Okado², Nancy Leidy³ and Joan T. Merrill⁴, ¹Rheumatology, Columbia University Medical Center, New York, NY, ²Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ³Evidera, Bethesda, MD, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The LFA REALTM is designed as two complimentary disease activity measures in order to integrate clinician and patient input. The current report updates progress…
Abstract Number: 1748 • 2017 ACR/ARHP Annual Meeting
Cbl-b Associates with Bcl-6 and Is Differentially Expressed in Circulating Follicular T Helper Cells of Patients with Systemic Lupus Erythematosus
Jeffrey Hampton¹, Giancarlo R. Valiente², Armin Munir³, Takuma Tsuzuki Wada³, William Willis³, Nicholas A. Young³, Lai-Chu Wu⁴, Jian Zhang⁵ and Wael Jarjour³, ¹Immunology and Rheumatoloty, The Ohio State University Wexner Medical Center, Columbus, OH, ²Rheumatology & Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Biological Chemistry and Pharmacology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁵Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: Activation of polyclonal CD4+ T cells and B cells is a hallmark of human and murine lupus, which suggests a global defect in the…
Abstract Number: 2598 • 2017 ACR/ARHP Annual Meeting
The Effects of Tai Chi on Inflammatory Mediator Secretion in Systemic Lupus Erythematosus
Juliette Yedimenko¹, Evelyn Thomas², Brian Snoad³, Juhi Sharma², Misha Mobeen², Holly Steigelman¹, Alexa Meara⁴, Giancarlo R. Valiente⁵, Stacy P. Ardoin⁶, Nicole Powell⁷, John Sheridan⁷, Wael Jarjour⁸ and Nicholas A. Young³, ¹The Ohio State University Wexner Medical Center, Columbus, OH, ²The Ohio State University, Columbus, OH, ³Department of Internal Medicine, Division of Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Internal Medicine/Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁵Rheumatology & Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁶Pediatric & Adult Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁷Institute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, ⁸Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: Exercise and psychological stress have been shown to produce opposite effects on immunomodulation. Prior studies in patients with Systemic Lupus Erythematosus (SLE) have demonstrated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.